Normal Pressure Hydrocephalus Clinical Trial
Official title:
Adjustable Gravitational vs. Adjustable Differential Pressure Valves in Patients With Idiopathic Normal Pressure Hydrocephalus. Prospective Randomized Study.
The goal of the study is to verify theoretical benefit of ventriculoperitoneal shunting with MIETHKE M.blue® valve in patients with iNPH. The study is designed to assess walking and balance, urinary function, cognitive performance and quality of life before and after shunting and compare the results between the patients with MIETHKE M.blue® and MIETHKE proGAV 2.0® (with SA 2.0®) valves.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | January 1, 2023 |
Est. primary completion date | January 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Age of patients (between 60 and 85 years old) - Clinically suspected Normal Pressure Hydrocephalus (NPH) with at least gait and one other symptom from Hakim-Adams triad (incontinence or dementia) - maximal initial pressure of 20 cmH2O during lumbar infusion test - Rout during LIT >9mmHg/ml*min - at least 15% improvement in Gait scale score after ELD - Conclusion of neuropsychological examination suggestive of iNPH (based on MoCA, Test of phonemic and verbal fluency, RAVLT, ROCFT, TMT A and B, Subtest of WAIS III, GDS) Exclusion Criteria: - Aetiology of hydrocephalus other than idiopathic normal pressure hydrocephalus (secondary normal pressure hydrocephalus - history of meningitis or subarachnoid haemorrhage, obstructive type of hydrocephalus - eg aqueductal stenosis, Blake's pouch cyst) - Intracranial tumor - Other neurodegenerative diseases may be present (AD, Parkinson's disease, Lewy body dementia, Progressive supranuclear palsy and cerebrovascular diseases), however have to be mild and evaluated in neurological, neuropsychological examinations and on MRI |
Country | Name | City | State |
---|---|---|---|
Czechia | Neurosurgical department of the Central Military Hospital, 1st Faculty of Medicine of Charles University | Praha |
Lead Sponsor | Collaborator |
---|---|
Military University Hospital, Prague |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Dutch Gait scale in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | The Gait Scale, a useful quantitative measure of gait impairment in NPH patients, is a component of a larger measure developed as part of the Dutch normal pressure hydrocephalus study (Boon et al., 1997). The Gait Scale evaluates various aspects of gait, including walking speed, number of steps, stride length, stance, foot-floor clearance, balance, tandem walking ability, turning ability, and start hesitation in 10m of walking. (Ravdin et al., 2008) The score consists of 3 subcategories and ranges 2-40 points with higher score indicating more severe impairment. | Month 3/Year 1 | |
Primary | Change in MoCA in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | The Montreal Cognitive Assessment (MoCA) is a widely used screening assessment for detecting cognitive impairment. It was created in 1996 by Ziad Nasreddine in Montreal, Quebec. The MoCA assesses several cognitive domains. Score ranges 0-30 points with lower scores indicating more severely impaired cognitive skills. | Month 3/Year 1 | |
Primary | Change in ICIQ UI-SF in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | The ICIQ-UI Short Form is a questionnaire for evaluating the frequency, severity, impact on quality of life (QoL) and simple estimation of a cause of urinary incontinence in men and women. The score ranges 0-21 points with higher score indicating more severe impairment. | Month 3/Year 1 | |
Primary | Change in Kiefer Score in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | The Kiefer is a modified clinical grading tool that measures the severity of the three key symptoms (mental deficits, gait disturbance, incontinence) and two additional minor symptoms (headache and dizziness). The overall score may reach values between 0 and 24, with higher scores indicating more severe impairment | Month 3/Year 1 | |
Primary | Change in SF12 v 2.0 Health Survey in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | The SF-12® V2 Health Survey (SF-12 v2.0) (Ware, Kosinski, Turner-Bowker, & Gandek, 2002) is a 12-item questionnaire used to assess generic health outcomes from the patient's perspective. Generic patient-reported outcome (PRO) measures like the SF-12 assess general health and well-being [or health-related quality of life (HRQOL)], including the impact of any and all illnesses on a broad range of functional domains. The SF-12 v2 consists of a subset of 12 items from the SF-36® Health Survey (SF-36) (Ware & Sherbourne, 1992; Ware, Snow, Kosinski, & Gandek, 1993) covering the same eight domains of health outcomes, including physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH). | Month 3/Year 1 | |
Secondary | Postoperative changes in valve settings in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | Any change in the valve settings postoperatively will be recorded together with a degree of individual changes. | 1 Year | |
Secondary | Overdrainage in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | Headaches, dizziness, subdural effusions on imaging methods (MRI, CT) and any unplanned visits will be recorded. Chronic subdural haematomas will be divided to symptomatic/asymptomatic and number of drainages will be recorded. | 1 Year | |
Secondary | Shunt revisions in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | Any shunt revisions will be recorded together with a cause (malfunction etc.) | 1 Year | |
Secondary | Shunt related infections in MIETHKE M.blue® vs. MIETHKE proGAV 2.0® (with SA 2.0®) | Any shunt related infection will be recorded. | 1 Year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00149721 -
Anterior Pituitary Function in Patients With Hydrocephalus
|
N/A | |
Completed |
NCT00196196 -
A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.
|
Phase 3 | |
Not yet recruiting |
NCT05562596 -
Normal Pressure Hydrocephalus Biomarkers Investigation
|
||
Completed |
NCT00233701 -
Normal Pressure Hydrocephalus (NPH) Registry
|
Phase 4 | |
Unknown status |
NCT00874198 -
European Study on Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus
|
N/A | |
Withdrawn |
NCT00793416 -
ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients
|
Phase 4 | |
Recruiting |
NCT05910944 -
European Study of Prodromal iNPH
|
||
Active, not recruiting |
NCT01909960 -
Flow MRI in Normal Pressure Hydrocephalus
|
N/A | |
Completed |
NCT02016352 -
Cerebrospinal Fluid Proteome in Hydrocephalus
|
N/A | |
Terminated |
NCT01092546 -
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
|
Phase 3 | |
Completed |
NCT01815775 -
Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery
|
Phase 0 | |
Terminated |
NCT00613886 -
Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus
|
N/A | |
Recruiting |
NCT03877107 -
Effect of Depletive Lumbar Puncture on Lower Urinary Tract Dysfunction in iNPH
|
N/A | |
Enrolling by invitation |
NCT03269201 -
Brain Network Activation in Patients With Movement Disorders
|
||
Recruiting |
NCT03245138 -
Endoscopic Third Ventriculostomy Versus Ventriculo-peritoneal Shunting in Idiopathic Normal Pressure Hydrocephalus
|
N/A | |
Terminated |
NCT00727142 -
Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus (INPH)
|
N/A | |
Recruiting |
NCT04471740 -
Normal Pressure Hydrocephalus and Sleep Apnea
|
N/A | |
Completed |
NCT01798641 -
A Randomized Cross-over Study for Normal Pressure Hydrocephalus
|
N/A | |
Recruiting |
NCT01618500 -
Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus
|
N/A | |
Completed |
NCT00600795 -
Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
|
N/A |